scholarly journals Investigating the Factors Associated with the Level of Expression of Estrogen and Progesterone Receptors in Patients Suffering from Colorectal Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Saleheh Salehi far ◽  
Maryam Soltani ◽  
Mahmoud Zardast ◽  
Mohammad Reza Ghasemian Moghaddam
Keyword(s):  
Colorectal Cancer ◽  
Drugs Of Abuse ◽  
Progesterone Receptors ◽  
Advanced Stage ◽  
Estrogen And Progesterone Receptors ◽  
Familial History ◽  
Factors Associated ◽  
The Status ◽  
The Mean ◽  
Estrogen And Progesterone Receptor

Background. The present study was performed to investigate the factors related to the expression level of estrogen and progesterone receptor in patients with colorectal cancer. Material and Methods. This crosssectional study was performed on 54 patients suffering from colorectal cancer referring to Imam Reza Hospital in Birjand during 2018-2019. After the biopsy performed during surgery, the specimen was sent for immunohistochemistry, and the status of receptors was determined. Eventually, the data were analyzed by SPSS 22. Results. Out of the 54 patients studied, 64.8% were male. The mean age of the patients was 62.28 ± 14.03 years. The level of expression of beta-estrogen receptors and progesterone receptors had a significant relationship with age, consuming drugs of abuse, and familial history ( P = 0.001 ). Also, the level of expression of estrogen and progesterone receptors of patients with a more advanced stage of cancer was significantly lower ( P = 0.001 ). Conclusion. The extent of expression of estrogen and progesterone receptors affects the progression and prognosis of disease. Thus, through hormone therapy, a step can be taken to reduce the progression and even to treat colorectal cancer.

Estrogen and Progesterone Receptors in Meningiomas: Comparison of Nuclear Binding, Dextran-Coated Charcoal, and Immunoperoxidase Staining Assays

Neurosurgery ◽  
1989 ◽  
Vol 25 (4) ◽  
pp. 546-553 ◽  
Author(s):  
Jaroslava Halper ◽  
Douglas S. Colvard ◽  
Bernd W. Scheithauer ◽  
Nai-Siang Jiang ◽  
Michael F. Press ◽  
...  
Keyword(s):  
Estrogen Receptors ◽  
Steroid Receptors ◽  
Progesterone Receptors ◽  
Immunoperoxidase Staining ◽  
Estrogen And Progesterone Receptors ◽  
High Affinity ◽  
Nuclear Binding ◽  
Dextran Coated Charcoal ◽  
The Status

Abstract We studied the status of estrogen (ER) and progesterone (PR) receptors in meningiomas removed from 52 patients, comparing dextran-coated charcoal (DCC), nuclear binding (NB), and immunoperoxidase (IP) assays. Each of the assays was performed independently by investigators well-experienced with these assays. The NB assay is a new assay that measures functional steroid receptors—that is, the activation of the receptor and its binding to the nucleus. The assay is very sensitive and requires a relatively small amount of tissue as compared with the DCC assay. In agreement with data from other studies, PR were detected in most meningiomas by all 3 methods: in 69% of the cases by NB, in 76% by DCC, and in 89% by IP. ER were detected in only a few cases: in 33% by NB, in 2% by DCC, and in none by the IP assay. The agreement for PR sites was 62% for all 3 assays, it was 66% between the NB and DCC assays, 67% between the NB and IP assays, and 86% between the DCC and IP assays. Of 26 cases that were positive by the DCC assay, 6 (23%) were negative by NB. The overall agreement for all three ER assays was 65%. The data suggest that the majority of meningiomas contain high-affinity receptors for progesterone, that estrogen receptors are present in only a few meningiomas, and that some of these estrogen and progesterone receptors appear to be functional.

Estrogen and Progesterone Receptors in Human Colorectal Tumour Cells (Study of 70 Cases)

1988 ◽  
Vol 3 (1) ◽  
pp. 41-48 ◽  
Author(s):  
G. Bracali ◽  
A.M. Caracino ◽  
F. Rossodivita ◽  
C. Bianchi ◽  
M.G. Loli ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Estrogen Receptors ◽  
Progesterone Receptors ◽  
Human Colorectal Cancer ◽  
Estrogen And Progesterone Receptors ◽  
Colorectal Tumour ◽  
Estrogen Receptor Positive ◽  
Cytochemical Technique

Estrogen and progesterone receptors were studied in 70 cases of human colorectal cancer by a cytochemical technique. 28.5% of the cases were estrogen-receptor positive and 42.8% progesterone-receptor positive. There was no difference between the sexes for estrogen receptors but the women had more tumours with progesterone receptors than men. The presence of receptors is unrelated to the differentiation of the tumour. More colon tumours were positive than those of the sigma and rectum. The concentration of cells with receptors in positive cancer cases tended to be low or medium-low.

Advanced Stage of Disease and Systemic Inflammation as Factors Associated With Referral of Patients With Colorectal Cancer to a Palliative Care Unit

2020 ◽  
Vol 37 (10) ◽  
pp. 859-865
Author(s):  
Thiago Huaytalla Silva ◽  
Wilza Arantes Ferreira Peres ◽  
Karla Santos da Costa Rosa ◽  
Arthur Orlando Correa Schilithz ◽  
Livia Costa de Oliveira ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Palliative Care ◽  
Systemic Inflammation ◽  
Tumor Stage ◽  
Palliative Care Unit ◽  
Disease Stage ◽  
Advanced Stage ◽  
Hospital Unit ◽  
Factors Associated ◽  
Advanced Disease Stage

Objective: To identify factors associated with referral to an exclusive palliative care unit (PCU) in patients with colorectal cancer (CRC). Methods: Retrospective cohort study with patients having CRC of both sexes treated at a hospital unit, aged ≥20 years. Data were extracted from the medical records of pretreatment patients between January 2008 and August 2014. The outcome was referral to the PCU within 5 years. Logistic regression analyses were performed to assess whether sociodemographic, clinical, nutritional, and biochemistry data were associated to referral, generating odds ratios (OR), and 95% confidence intervals (CI). Results: Four hundred fifteen patients were evaluated. The Patient-Generated Subjective Global Assessment demonstrated a prevalence of malnutrition of 57.3%. One hundred one (24.3%) patients were referred to the PCU after 16.3 months (interquartile range: 7.2-33.5). These patients were more likely to be at an advanced stage of the disease and have malnutrition and exacerbated systemic inflammation. Tumor stage III and IV (OR: 2.05; 95% CI: 1.12-3.76) and neutrophil-to-lymphocyte ratio (NLR) ≥3 (OR: 1.89; 95% CI: 1.12-3.17) were predictors of an increased chance of referral to the PCU. Conclusion: Advanced disease stage and NLR were associated with referral of patients with CCR to a PCU.

scholarly journals Acral Lentiginous Melanoma: Survival Analysis of 715 Cases

2018 ◽  
Vol 23 (1) ◽  
pp. 38-43 ◽  
Author(s):  
Leonardo S. Lino-Silva ◽  
César Zepeda-Najar ◽  
Rosa A. Salcedo-Hernández ◽  
Héctor Martínez-Said
Keyword(s):  
Clinicopathological Features ◽  
Stage I ◽  
Breslow Thickness ◽  
Advanced Stage ◽  
Acral Lentiginous Melanoma ◽  
Factors Associated ◽  
The Mean ◽  
Male Sex ◽  
Disease Specific ◽  
Aggressive Variant

Introduction: Acral lentiginous melanoma (ALM) is an aggressive variant of melanoma; the incidence, prevalence, and prognosis differ among populations. We analyzed clinicopathological features and survival in Hispanics, a population with high ALM prevalence. Material and Methods: From 1144 patients with melanoma, we analyzed 715 ALMs and 429 non-ALMs from the National Referral Cancer Centre and compared survival. Results: Of the ALM group, 62.8% were female; the median age was 58 years. The mean Breslow thickness was 3.56 ± 7.16 mm. ALM patients showed an estimated 5-year disease-specific survival (DSS) of 53.3%, 52.7%, and 40.8% for stage I, II, and III, respectively. For non-ALM patients, the DSS rates were 66%, 60.8%, and 48.4% for stage I, II, and III disease, respectively. Overall, the 1-, 3-, and 5-year DSS rates for patients with ALM were 85.1%, 59.4%, and 46.3%, respectively; for non-ALM patients, they were 81.3%, 64.8%, and 55.7%, respectively ( P = .168). In the multivariate analysis, factors associated with decreased DSS were high Breslow thickness, recurrence, ulceration, male sex, and advanced stage. Conclusions: The 1-, 3-, and 5-year DSS rates of patients with ALM were not statistically different from those of non-ALM patients. In addition to known adverse prognostic factors, male sex was also associated with worse survival.

Estrogen and Progesterone Receptors in Colorectal Cancer and Surrounding Mucosa

2001 ◽  
Vol 16 (4) ◽  
pp. 262-267 ◽  
Author(s):  
P. Raigoso ◽  
L. Sanz ◽  
F. Vizoso ◽  
B. Llana ◽  
I. Quintela ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Survival ◽  
Progesterone Receptors ◽  
Normal Mucosa ◽  
Tumor Location ◽  
Histological Differentiation ◽  
Er Positive ◽  
The Mean ◽  
Low Levels

In this prospective study we have quantified by means of ELISA-methods the cytosolic content of estrogen (ER) and progesterone receptors (PgR) in tumoral tissue and paired normal mucosa from 163 patients with resectable colorectal cancer. Survival analysis was performed in a subgroup of 120 patients and the mean follow-up period was 24.9 months. The cutoff for ER and PgR levels was set at 1 fmol/mg protein. On the basis of this cutoff 20.9% of the cancers were ER positive and 25.8% were PgR positive; normal adjacent tissue presented ER in 18.4% and PgR in 24.5%. Our results did not show any significant correlation between ER and PgR levels in neoplastic tissues. Howewer, a correlation was found in normal mucosa samples (p=0.02). Statistical analysis showed that there was no correlation between tumor ER and PgR content and patient age or sex, tumor location, Dukes’ stage, histological differentiation, DNA ploidy status and S-phase fraction. Furthermore, the results did not show any statistical differences in relapse-free and overall survival curves calculated for patients classified according to the hormone receptor content of their tumors. ER and PgR were detected at low levels in normal and neoplastic colorectal tissues without any significant relationship to either clinicopathological tumor characteristics or patient outcome. Their possible role in colorectal cancer remains to be elucidated.

Does advanced-stage endometriosis affect the gene expression of estrogen and progesterone receptors in granulosa cells?

2011 ◽  
Vol 95 (3) ◽  
pp. 889-894 ◽  
Author(s):  
Masako Karita ◽  
Yoshiki Yamashita ◽  
Atsushi Hayashi ◽  
Yoko Yoshida ◽  
Mika Hayashi ◽  
...  
Keyword(s):  
Gene Expression ◽  
Granulosa Cells ◽  
Progesterone Receptors ◽  
Advanced Stage ◽  
Estrogen And Progesterone Receptors

scholarly journals American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

2010 ◽  
Vol 6 (4) ◽  
pp. 195-197 ◽  
Author(s):  
M. Elizabeth H. Hammond ◽  
Daniel F. Hayes ◽  
Antonio C. Wolff ◽  
Pamela B. Mangu ◽  
Sarah Temin
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Progesterone Receptors ◽  
Evidence Based ◽  
Estrogen And Progesterone Receptors ◽  
Testing Performance ◽  
American Society ◽  
Evidence Based Guideline ◽  
Immunohistochemical Testing ◽  
Estrogen And Progesterone Receptor

ASCO and CAP collaborated to produce an evidence-based guideline on estrogen and progesterone receptor testing in breast cancer to produce optimal testing performance.

Use of the vertical rotor to facilitate estrogen and progesterone receptor analysis.

1978 ◽  
Vol 24 (9) ◽  
pp. 1609-1611 ◽  
Author(s):  
L F Hofman ◽  
C Moline ◽  
G McGrath ◽  
E J Barron
Keyword(s):  
Progesterone Receptor ◽  
Gradient Analysis ◽  
Tumor Tissue ◽  
Clinical Laboratory ◽  
Progesterone Receptors ◽  
Sucrose Density Gradient ◽  
Estrogen And Progesterone Receptors ◽  
Vertical Rotor ◽  
Mammary Tumor Tissue ◽  
Estrogen And Progesterone Receptor

Abstract Sucrose density-gradient analysis is one method of identifying specific estrogen and progesterone receptors in mammary tumor tissue. Use of the vertical rotor makes this practical for routine applications in the clinical laboratory by increasing the number of samples that can be run at one time and shortening the centrifuge time from 18 to less than 2 h. The separations and reproducibility compare favorably with those obtained with a swinging-bucket rotor.

scholarly journals Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer

Genes ◽  
2021 ◽  
Vol 12 (4) ◽  
pp. 582
Author(s):  
Tatiana Kalinina ◽  
Vladislav Kononchuk ◽  
Efim Alekseenok ◽  
Darya Obukhova ◽  
Sergey Sidorov ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Lymph Node ◽  
Progesterone Receptors ◽  
Estrogen And Progesterone Receptors ◽  
Ki 67 ◽  
Aberrant Expression ◽  
Node Metastasis ◽  
Cancer Initiation ◽  
The Status

In ~70% of breast cancer (BC) cases, estrogen and progesterone receptors (ER and PR) are overexpressed, which can change during tumor progression. Expression changes of these receptors during cancer initiation and progression can be caused by alterations in microRNA (miR, miRNA) expression. To assess the association of BC progression with aberrant expression of miRNAs that target ER and PR mRNAs, we quantified miR-19b, -222, -22, -378a, and -181a in BC samples (n = 174) by real-time PCR. Underexpression of miR-222 and miR-378a in stage T2–T4 BC was characteristic for HER2-overexpressing tumors. In addition, the expression of miR-181a and miR-378a was higher in these tumors than in tumors with a HER2 IHC score of 0 or 1+. In tumors with a Ki-67 index ≥ 14%, all tested miRNAs were underexpressed in BC with a high Allred PR score (6–8). In ER-and-PR–negative tumors, miR-22, miR-222, miR-181a, and miR-378a underexpression was associated with Ki-67 index > 35% (median value). MiR-19b and miR-22 underexpression could be a marker of lymph node metastasis in ER- and/or PR-positive tumors with HER2 IHC score 0. Thus, the association of miR-19b, miR-22, miR-222, miR-378a, and miR-181a levels with BC characteristics is influenced by the status of tumor ER, PR, HER2, and Ki-67.

scholarly journals Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the “interval cancer” perspective

2022 ◽  
Author(s):  
Thuy Ngan Tran ◽  
Marc Peeters ◽  
Sarah Hoeck ◽  
Guido Van Hal ◽  
Sharon Janssens ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Interval Cancer ◽  
High Grade ◽  
Advanced Stage ◽  
Minimal Impact ◽  
Faecal Immunochemical Test ◽  
Factors Associated ◽  
Screening Interval ◽  
Immunochemical Test ◽  
The Impact

Abstract Background Interval cancer (IC) is a critical issue in colorectal cancer (CRC) screening. We identified factors associated with ICs after faecal immunochemical test (FIT) screening and explored the impact of lowering FIT cut-off or shortening screening interval on FIT-ICs in Flanders. Methods FIT participants diagnosed with a CRC during 2013–2018 were included. Factors associated with FIT-ICs were identified using logistic regression. Distributions of FIT results among FIT-ICs were examined. Results In total, 10,122 screen-detected CRCs and 1534 FIT-ICs were included (FIT-IC proportion of 13%). FIT-ICs occurred more frequently in women (OR 1.58 [95% CI 1.41–1.76]) and ages 70–74 (OR 1.35 [1.14–1.59]). FIT-ICs were more often right-sided (OR 3.53 [2.98–4.20]), advanced stage (stage IV: OR 7.15 [5.76–8.88]), and high grade (poorly/undifferentiated: OR 2.57 [2.08–3.18]). The majority (83–92%) of FIT-ICs would still be missed if FIT cut-off was lowered from 15 to 10 µg Hb/g or screening interval was shortened from 2 to 1 year. Conclusions FIT-ICs were more common in women, older age, right-sided location, advanced stage and high grade. In Flanders, lowering FIT cut-off (to 10 µg Hb/g) or shortening screening interval (to 1 year) would have a minimal impact on FIT-ICs.

Sign in / Sign up

Export Citation Format

Share Document